AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
China SXT Pharmaceuticals, Inc.
Video analysis: SXTC
All videosNo video analysis for this stock yet. Request one from our team.
News: SXTC
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company”), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the “Share Consolidation”). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on August 10, 2026.
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $9 million for its client China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
TAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a “Unit”), consisting of one Class A ordinary share of the Company, no par value per share (each, a “Class A ordinary share”), and one common warrant (each, a “Warrant”), at a purchase price of $2.00 per Unit in a registered direct offering.
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 37.4% in June
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC - Get Free Report) was the recipient of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 45,019 shares, a drop of 37.4% from the June 15th total of 71,896 shares. Based on an average daily volume of 50,754
Similar companies
-
Tonix Pharmaceuticals Holding Corp.
TNXP
·
NASDAQ
Compare
-
Incannex Healthcare Limited
IXHL
·
NASDAQ
Compare
-
Anteris Technologies Global Corp.
AVR
·
NASDAQ
Compare
-
Fate Therapeutics, Inc.
FATE
·
NASDAQ
Compare
-
Innate Pharma S.A.
IPHA
·
NASDAQ
Compare
-
Milestone Pharmaceuticals Inc.
MIST
·
NASDAQ
Compare